Lungpacer

Vancouver, Canada Founded: 2009 • Age: 17 yrs
Neurostimulation-based pacer for diaphragm strength is developed.
Request Access

About Lungpacer

Lungpacer is a company based in Vancouver (Canada) founded in 2009.. Lungpacer has raised $121.38 million across 7 funding rounds from investors including Canadian Institutes of Health Research and Military Health. Lungpacer offers products and services including AeroPace System and AeroNova System. Lungpacer operates in a competitive market with competitors including Belluscura, hemovent, ALung, OneBreath and Securisyn, among others.

  • Headquarter Vancouver, Canada
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Lungpacer Medical, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $121.38 M (USD)

    in 7 rounds

  • Latest Funding Round
    $10 M (USD), Series B

    Mar 18, 2025

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Lungpacer

Lungpacer offers a comprehensive portfolio of products and services, including AeroPace System and AeroNova System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Stimulates diaphragm to aid weaning from mechanical ventilation.

Used for clinical investigations in breathing support technologies.

People of Lungpacer
Headcount 50-200
Employee Profiles 24
Board Members and Advisors 17
Employee Profiles
People
Judy Ways
VP, Regulatory Affairs
People
Jessica C.
Quality Assurance Associate
People
Doug Evans
President & CEO
People
Nawzer Mehta
SVP, Clinical Affairs

Unlock access to complete

Board Members and Advisors
people
Joshua O. Benditt
Clinical Board Member
people
Rich Branson
Clinical Board Member
people
Ralf Ewert
Clinical Board Member
people
Dean Hess
Clinical Board Member

Unlock access to complete

Funding Insights of Lungpacer

Lungpacer has successfully raised a total of $121.38M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $10 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 7
  • Last Round Series B — $10.0M
  • First Round

    (13 Mar 2013)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2025 Amount Series B - Lungpacer Valuation

investors

Apr, 2022 Amount Series B - Lungpacer Valuation

investors

Jan, 2021 Amount Grant - Lungpacer Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Lungpacer

Lungpacer has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Canadian Institutes of Health Research and Military Health. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Administers health care and support for military personnel and operations.
Founded Year Domain Location
Health research projects in Canada are funded and supported.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Lungpacer

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Lungpacer

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Lungpacer Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Lungpacer

Lungpacer operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Belluscura, hemovent, ALung, OneBreath and Securisyn, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of medical devices for laparoscopic procedures
domain founded_year HQ Location
Equipment for extracorporeal life support and CO2 removal is developed.
domain founded_year HQ Location
Extracorporeal CO2 removal systems are developed to supplement mechanical ventilation.
domain founded_year HQ Location
Portable mechanical ventilators for intensive care patients are developed.
domain founded_year HQ Location
Endotracheal tube stabilization systems for ventilated patients are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Lungpacer

Frequently Asked Questions about Lungpacer

When was Lungpacer founded?

Lungpacer was founded in 2009 and raised its 1st funding round 4 years after it was founded.

Where is Lungpacer located?

Lungpacer is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.

Who is the current CEO of Lungpacer?

Doug Evans is the current CEO of Lungpacer.

Is Lungpacer a funded company?

Lungpacer is a funded company, having raised a total of $121.38M across 7 funding rounds to date. The company's 1st funding round was a Grant of $5.36M, raised on Mar 13, 2013.

What does Lungpacer do?

Lungpacer was founded in 2009 in Vancouver, Canada, within the medical device sector focused on respiratory health. A neurostimulation system is provided by the company, utilizing minimally invasive transvascular technology to activate the diaphragm. Electrodes are inserted intravenously to enable rhythmic stimulation, restoring negative pressure ventilation. Pacing therapy is applied to prevent or reverse diaphragm muscle atrophy and sustain endurance. Operations center on this technology for clinical applications.

Who are the top competitors of Lungpacer?

Lungpacer's top competitors include Belluscura, hemovent and ALung.

What products or services does Lungpacer offer?

Lungpacer offers AeroPace System and AeroNova System.

Who are Lungpacer's investors?

Lungpacer has 2 investors. Key investors include Canadian Institutes of Health Research, and Military Health.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available